Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: The case for

Genitourinary Medicine

Volumn 73, Issue 3, 1997, Pages 216-218

  Moyle, Graeme J ^a   Gazzard, Brian G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030744776     PISSN: 02664348     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.73.3.216     Document Type: Short Survey

References (33)

1. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immune deficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1099-106.
2. Hammer SM, Katzenstein DA, Hughes MD, Gundacker M, Hirsch M, Merrigan T, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200-500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
3. DELTA Co-ordinating Committee. DELTA: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine or zidovudine alone in HIV infected individuals. Lancet 1996;348:283-91.
4. Lalezari J, Haubrich R, Burger HU, Beattie D, Donatacci L, Salgo M, et al. Improved survival and decreased disease progression of HIV in patients treated with saquinavir plus HIVID. IXth International Conference on AIDS. Vancouver, July 1996; abstract LB, B6033.
5. Katlama C on behalf of the CAESAR co-ordinating committee. Clinical and survival benefit of 3TC in combination with zidovudine-containing regimens in HIV-1 infection: interim results of the CAESAR study. 3rd International Congress on Drug Therapy in HIV infection. Birmingham, November 1996: abstract SS2·1.
6. Katzenstein DA, Hammer SM, Hughes MD, Gundaker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
7. O'Brien WA, Hartigan P, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-43.
8. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996;124:654-63.
9. Prentice RL. Surrogate endpoints in clinical trials. Stat Med 1989;8:431-40.
10. Hughes MD, De Gruttola V, Welles SL. Evaluating surrogate markers. J Acquir Immune Defic Syndr Hum Retrovirus 1995;10 (Suppl 2):S1-S8.
11. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in the plasma. Science 1996;272: 1167-70.
12. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency type 1 infection. N Engl J Med 1995;332:201-8.
13. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, et al. Studies in subject with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-16.
14. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770-6.
15. Fernandez-Cruz E, Desco M, Garcia Montes M, Longo N, Gonzalez B, Zabay JM. Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users. AIDS 1990;4:987-94.
16. Phillips AN, Elford J, Sabin C, Bofill M, Janoussy G, Lee C. Immunodeficiency and the risk of death in HIV infection. JAMA 1992;268:2662-6.
17. Hanson DL, Horsburgh CR, Fann SA, Havlik JA, Thompson SE. Survival prognosis of HIV infected patients. J Acquir Immune Defic Syndr 1993;6:624-9.
18. Masur H, Ognibene FP, Yarchoan R, Stelhamer JH, Baird BF, Travis E, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989;111:223-31.
19. Neaton JD, Wentworth DN, Rhame F, Hogan C, Abrams DI, Deyton L for the Terry Beirn Community Programs for Clinical research on AIDS (CPCRA). Methods of studying interventions: considerations in choice of a clinical endpoint for AIDS trials. Stat Med 1994;13: 2107-25.
20. + lymphocytes are an incomplete surrogate marker for clinical disease progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993; 118:674-80.
21. Lin D, Fischl MA, Schoenfeld D. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 1993;12:835-42.
22. + lymphocyte counts and HIV-1 production by cells. Science 1996;271:670-1.
23. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, Ritonavir. J Infect Dis 1996;173: 321-9.
24. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373: 123-6.
25. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
26. Liuzzi G, Chiriani A, Clementi M, Bagnarelli P, Valenza A, Cataldo PT, Piazza M. Analysis of HIV-1 load in blood, semen, and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS 1996;10:F51-6.
27. Lafeuillade A, Djediouane A, Poggi C, Profizi N, Costes O, Tamalet C. Kinetics of viral clearance in plasma, peripheral blood mononulear cells and lymph nodes. AIDS 1996;10:801-2.
28. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin L. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995;9:159-63.
29. Coombs RW, Welles SL, Hooper C, Reichenfelder PS, D'Aquilla RT, Japour AJ, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-12.
30. Phillips AN, Eron JJ, Bartlett JA, Rubin M, Johnson J, Price S, et al. HIV-1 RNA levels and the development of clinical disease. AIDS 1996;10:859-65.
31. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nature Med 1996;2:625-9.
32. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, Feinberg MB. Activation, of virus replication after vaccination of HIV-infected individuals. J Exp Med 1995;182:1727-37.
33. Donavon RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. Changes in virus load markers during AIDS-associated opportunistic diseases in HIV-infected persons. J Infect Dis 1996;174:401-3.